Publications by authors named "F Dignan"
Article Synopsis
- * A significant number of respondents (67.0%) felt that early diagnosis was challenging, but many (75.8%) found the new 2023 EBMT diagnostic criteria useful and easy to apply.
- * Key risk factors for VOD/SOS included second allo-HCT, pre-existing liver disease, and prior use of antibody-drug conjugates, with varied preferences on when to start treatment.
Article Synopsis
- Established KIR clinical assessment algorithms for selecting donors in hematopoietic progenitor cell transplantation (HPCT) focus mainly on the gene content of KIR, while the impact of KIR allelic polymorphism remains less understood.
- This study analyzed the effects of specific KIR2DL1 alleles (particularly polymorphic residues at codons 114 and 245) on post-transplant outcomes in a cohort of 86 acute myelogenous leukemia patients undergoing T cell depleted reduced intensity conditioning HPCT.
- The findings revealed that KIR2DL1*003 positive donors significantly worsened 5-year overall survival and disease-free survival rates, while also increasing relapse incidence compared to KIR2DL1*003 negative donors
Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can develop after hematopoietic cell transplantation (HCT). A new definition for diagnosis, and a severity grading system for SOS/VOD in adult patients, was reported a few years ago on behalf of the European Society for Blood and Marrow Transplantation (EBMT). The aim of this work is to update knowledge regarding diagnosis and severity assessment of SOS/VOD in adult patients, and also its pathophysiology and treatment.
View Article and Find Full Text PDFIntroduction: COVID-19 has been associated with high morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients.
Methods: This study reports on 986 patients reported to the EBMT registry during the first 29 months of the pandemic.
Results: The median age was 50.
Haematopoietic stem cell transplant (HSCT) recipients have deficiencies in their adaptive immunity against vaccine preventable diseases. National and International guidance recommends that HSCT recipients are considered 'never vaccinated' and offered a comprehensive course of revaccination. This position statement aims to draw upon the current evidence base and existing guidelines, and align this with national vaccine availability and licensing considerations in order to recommend a pragmatic and standardised re-vaccination schedule for adult and paediatric HSCT recipients in the UK.
View Article and Find Full Text PDF